According to Hybio Pharmaceutical, on the afternoon of December 31, 2024, a delegation from Huawei Technologies Co., Ltd. comprising four members, including Li Songmeng, General Manager of the Shenzhen Government Enterprise Pan Enterprise System Department, Dong Wei, Minister of the Shenzhen Government Enterprise Intelligent Manufacturing Expansion Department, Wang Xiang, Director of the Shenzhen Cloud Native Biomedical Solutions, and Dai Yunlong, representative of the Shenzhen Government Enterprise Biomedical Industry, visited Hybio Pharmaceutical for exchange and cooperation discussions. During the visit to Hybio Pharmaceutical's product exhibition hall and research and development center, the Huawei delegation gained an in-depth understanding of Hybio Pharmaceutical's strategic vision, development history, product pipeline, and research and development technology. In the subsequent discussion, both parties extensively explored the applications of Huawei's Cloud Pangu large molecular model in drug design and development, peptide platform construction, and digital transformation empowering corporate efficiency improvement, as well as the application prospects of AI in the Global pharmaceutical industry.